Danaher Co. (NYSE:DHR) Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 1.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 201,330 shares of the conglomerate’s stock after acquiring an additional 2,030 shares during the period. Calamos Advisors LLC’s holdings in Danaher were worth $46,215,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB purchased a new position in shares of Danaher in the 3rd quarter worth $5,923,000. Czech National Bank lifted its stake in shares of Danaher by 4.2% in the 3rd quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock valued at $36,404,000 after purchasing an additional 5,320 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Danaher by 33.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,480 shares of the conglomerate’s stock worth $1,246,000 after purchasing an additional 1,125 shares during the period. WealthBridge Capital Management LLC increased its position in Danaher by 51.8% during the 3rd quarter. WealthBridge Capital Management LLC now owns 1,465 shares of the conglomerate’s stock worth $407,000 after purchasing an additional 500 shares in the last quarter. Finally, Diversified Trust Co lifted its position in Danaher by 29.6% during the third quarter. Diversified Trust Co now owns 5,649 shares of the conglomerate’s stock valued at $1,571,000 after buying an additional 1,289 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

DHR opened at $214.09 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market cap of $154.64 billion, a price-to-earnings ratio of 40.55, a PEG ratio of 2.80 and a beta of 0.83. Danaher Co. has a 1-year low of $214.03 and a 1-year high of $281.70. The company’s fifty day moving average price is $235.40 and its two-hundred day moving average price is $253.09.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business earned $2.09 earnings per share. On average, analysts expect that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is currently 20.45%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Wells Fargo & Company dropped their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. KeyCorp increased their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Citigroup cut their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.